Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have demonstrated effectiveness for advanced hepatocellular carcinoma (HCC). However, the discrepancy in the efficacy of ICIs in HCC patients with distinct etiologies has not been systematically validated. Methods: PubMed, MEDLINE, Embase, clinicaltrials.gov, and abstracts from ASCO and ESMO conferences were searched for eligible trials that explored the impact of etiology factor on the ICI treatment in HCC patients. The pooled hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS), as well as the pooled odds ratio (OR) of objective response rate (ORR), were calculated with stratification of hepatitis B virus (HBV), hepatitis C virus (HCV) and nonviral subgroup, and the heterogeneity between different etiological subgroups was assessed by using an interaction test. Results: Eight eligible studies with a total of 5,646 patients were identified from searching published articles and conference abstracts. ICI therapies were associated with significantly prolonged OS with the pooled HRs of 0.78 (95% CI 0.73–0.84, p < 0.001), 0.71 (95% CI 0.65–0.79, p < 0.001), 0.80 (95% CI 0.69–0.93, p = 0.003), and 0.87 (95% CI 0.77–0.97, p = 0.011) for the whole population, HBV subgroup, HCV subgroup, and non-viral subgroup, respectively. In addition, this analysis reported a significant PFS improvement with ICI therapies with HRs of 0.78 (p = 0.004), 0.53 (p < 0.001), 0.65 (p = 0.011), and 0.81 (p = 0.107) for whole population, HBV, HCV, and nonviral subgroup, respectively. The HBV-related HCC patients showed the more distinctive HRs for OS and PFS than other etiology subgroups, and this difference was significant in PFS (p for heterogeneity = 0.001), and there was a tendency of significance in OS (p for heterogeneity = 0.079). Furthermore, the ORR advantages of ICI therapies over control were also confirmed with the pooled ORs of 3.62 (p < 0.001), 3.84 (p < 0.001), 3.05 (p < 0.001), and 2.99 (p < 0.001) for whole population, HBV, HCV, and nonviral population, respectively (p for heterogeneity = 0.743). Conclusions: ICI therapies significantly improve OS, PFS, and ORR for HCC patients with different etiologies. HBV-related HCC patients could be the highlighted population to benefit from ICI treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, viral status exhibited robust predictive performance in ICI therapy for hepatobiliary cancers, validating prior studies suggesting that HBV-associated hepatocellular carcinoma (HCC) patients are likely to benefit from ICIs therapy33.”
From Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 1×
“ICIs therapies showed signi fi cant improved survival versus TKIs in IMbrave 150 [6, 7] and ORIENT-32 [8] trials in the fi rst-line setting.”
MethodA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · cited 1×
“Since nivolumab and pembrolizumab were con fi rmed to be effective as second-line treat-ment for HCC [3 – 5], a growing number of clinical trials of ICIs have been launched worldwide.”
BackgroundZhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843 · cited 2×
“The immune environments mediated by different etiologies potentially in fl uence the tumor response to ICI therapies [25].”
BackgroundInfluential
Cited by
Yuan, H., Xu, R., Li, S., Zheng, M., Tong, Q., Xiang, M., & Zhang, Y. (2025) · MedComm · doi:10.1002/mco2.70121 · Cited by 48
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
“WhilesystemicICItherapymayleadtoviral reactivation 31 , studies suggest that certain viral infections not only fail to increasetheriskofvirus-associatedcomplicationsbutmayalsoenhanceICI ef fi cacybysuppressingviralreplication 32,33 .”
Zhang, S., Xu, H., Li, M., Yuan, G., Nie, J., Zhang, Q., Shi, J., Liu, D., Meng, H., Dong, W., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.026 · Cited by 27
Wang, K., Feng, J., Yu, H., Cheng, Y., Xiang, Y., Liu, Z., Qin, Y., Liu, E., Shan, Y., Chen, F., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02427-0 · Cited by 16
“1 in unresectable HCC. 43 During study design, we hypothesized that the novel combination of TACE with atezolizumab and bevacizumab could potentially elevate the ORR from 35% to 55%, though no formal statistical comparison was planned.”
InfluentialGuan, M., Li, N., Ding, Q., Sun, D., Li, H., Yang, M., Hong, L., & Zhu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1713151 · Cited by 6
Fang, R.-F., Sha, C., Xie, Q., Yao, D., & Yao, M. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206301453240910044913 · Cited by 10
Wang, G., Chen, F., Zhao, R., Liu, Z. M., Yang, X., & Luo, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1807408 · Cited by 4
“…does not impair the antitumor ef fi cacy of ICIs in HCC. Conversely, some studies indicate that patients with HBV-associated HCC may derive survival bene fi ts from ICIs that are comparable to, or even superior to, those of their non-viral counterparts (Supplementary Table 1) (Table 2) (88, 89).”
Zhang, S., Du, K., Gao, S., Liu, Z., Chen, L., Wu, X., & Li, L. (2025) · Human Genetics · doi:10.1007/s00439-025-02753-x · Cited by 3
Zhou, Y., Yao, M., Ma, J., Wen, T., & Zhang, X.-Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003918 · Cited by 2
Kuo, Y., Teng, W., Lin, P., Chen, Y., Su, C., Shen, E. Y.-L., Huang, B.-S., Wu, T., Cheng, J.-Y., Hsieh, Y., et al. (2025) · Liver International · doi:10.1111/liv.70465 · Cited by 2
“Consistently, meta-analyses of clinical trials [27, 28] have reported lower survival benefits from ICIs in non-viral HCC than in HBV/HCV-associated cases.”
Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC
Xiang, X., & Yu, Y. (2026) · Liver International · doi:10.1111/liv.70512 · Cited by 1
“Emerging data indicate that HBV-related HCC generally derives greater survival benefit from checkpoint inhibitors compared to non-viral or NASH-related HCC, which may harbour dysfunctional T cells resistant to immunotherapy [4].”
Watanabe, N., Kobayashi, T., Iwaki, M., Nogami, A., Wada, N., Shimizu, A., Komori, T., Koike, H., Sahashi, Y., Nakajima, A., et al. (2025) · JGH Open · doi:10.1002/jgh3.70163
“Administration of ICIs is more effective in HBV-derived HCC than in non-viral and HCV-derived cases [20].”
Yang, R., Lu, C., Jian, Q., Song, Y., Sun, B., He, W., Li, J., Yang, F., Wang, X., Tan, Z., et al. (2026) · The Innovation · doi:10.1016/j.xinn.2026.101274 · Cited by 7
Chang, P.-C., Yan, Z.-C., Hong, Y.-C., Kai-ting, Y., Hu, T.-Y., Wu, P., Lin, C.-C., Ko, T., Yang, J., Yang, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.06.723140
The China Paradox in LEAP-012 Trial
Kudo, M. (2026) · Liver Cancer · doi:10.1159/000552537
“Several systematic reviews and meta-analyses of randomized controlled trials have demonstrated that ICI-based therapies produce superior outcomes in HBV-related HCC [12–15] (Table 3).”
Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors
Liu, C., Chang, L., Yan, Y., Ji, H., Ma, J., Sun, H. S., & Wang, L. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01395-z
“Many clinical trials (i.e. COSMIC-312 [ 107], Check - Mate-459 [ 108 ], KEYNOTE-240 [ 109 ]) and meta-analyses [11, 110 ] suggest that patients with HBV-HCC respond better to ICI therapy and have a better prognosis compared to patients with non-viral HCC and HCV-HCC.”
Wang, R., Ren, B., Zhang, X., Liu, B., & Zhou, W. C. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01470-6
Zhu, J., Zhang, H., Wang, Z., & Cheng, S. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168333
Kim, H., Felismino, T. C., Licio, A., de Almeida, G. R., & Brito, A. B. C. D. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100371 · Cited by 1
“22 In contrast, no statistically significant benefit was observed in patients with BCLC stage C disease or HCV-related HCC; however, these findings should be interpreted with caution given the wide CIs and limited sample sizes within these subgroups.”
Virological Events During Immune Checkpoint Inhibitor Therapy: A Multi-Source Evaluation
Cao, Y., Zhang, Z., Liang, Y., Zhao, C., Li, X., Yang, Q., & Shao, L. (2026) · Pharmaceuticals · doi:10.3390/ph19101616
“This extends prior syntheses focused on efficacy and safety in viral hepatitis-associated hepatocellular carcinoma by addressing how virological findings are interpreted when they arise during treatment [50–52].”
Metadata
- Authors
- Du, Q., Yuan, J., & Ren, Z.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Ren, Zhenggang
- ORCID
- Ren, Zhenggang
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2023-10-30
- Volume
- 13
- Issue
- 4
- Pages
- 344-354
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC11250578
- OpenAlex
- W4388037928
- Semantic Scholar
- 405ad4d6e758adc3413050969d451445ce7da8b7
- Cited by
- 20
- References
- 30
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 1
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, immune checkpoint inhibitors, hepatitis B virus, hepatitis C virus, cancer etiology, overall survival, progression-free survival, objective response rate, advanced liver cancer, PD-1 inhibitors, CTLA-4 inhibitors, PD-L1 inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.